FIELD: biotechnology; chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an anti-MICA/MICB antibody or its antigen-binding fragment. Also disclosed is a pharmaceutical composition containing said antibody.
EFFECT: invention provides effective treatment of tumours associated with MICA.
16 cl, 8 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MICA/B ANTIBODIES AND METHODS OF USE | 2019 |
|
RU2821021C2 |
| ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
| NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUS B AND WAYS OF THEIR APPLICATION | 2015 |
|
RU2739952C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| NEUTRALIZING ANTIBODIES TO INFLUENZA B VIRUS AND THEIR APPLICATION METHODS | 2020 |
|
RU2784915C2 |
| METHODS FOR DETECTING FOLATE RECEPTOR 1 IN PATIENT SAMPLE | 2018 |
|
RU2759410C2 |
| HUMAN CYTOMEGALOVIRUS ANTIBODY AND USE THEREOF | 2020 |
|
RU2817217C1 |
| NEW ANTIBODIES AGAINST HEPATITIS B VIRUS AND APPLICATION THEREOF | 2020 |
|
RU2814471C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
